All In MedTech

Device Trial Radar · NCT03085433

Sperm Selection by Microfluidic Separation Improves Embryo Quality

Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 393 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

393

Actual

Start

Jun 20, 2017

Primary completion

Oct 30, 2021

Study completion Apr 30, 2022

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 21, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized controlled trial of couples with a history of poor embryo quality undergoing a repeat in vitro fertilization (IVF) cycle for unexplained infertility. Couples will be randomized to sperm selection by the clinical standard of centrifugation and density-gradient processing compared to the microfluidic sperm sorting chip.

Conditions

  • Sperm DNA Fragmentation
  • Embryo Quality
  • Fertility Disorders
  • Infertility
  • Infertility, Male
  • Infertility Unexplained

Interventions

  • Microfluidic Sperm SortingDevice

    Microfluidic technology isolates healthy sperm by laminar flow, creating gradients through channels. The microfluidic chip we plan to study in our randomized clinical trial utilizes space-constrained microfluidic sorting to select highly motile and morphologically normal sperm in a flow and chemical-free design. Unlike the standard of density gradient centrifugation, no manipulation of sperm is required in this process. Raw semen is introduced into the inflow and only motile and morphologically normal sperm are able to swim through the chip to the outflow where it is collected for use.

  • in vitro fertilizationProcedure

    ivf/icsi

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Day 3 High Quality Embryo PercentageTime frame: 3 days following fertilization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.